FarinaB, VenturiP, OnofriA, . Usefulness of a DSM criteria-based inventory for screening for post-traumatic stress disorder. Prehosp Disaster Med. 2007;22:454–456.
2.
De BerardisD, Di IorioG, AcciavattiT, . The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011;10:119–132.
3.
SteinDJ, AhokasAA, de BodinatC.Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:561–566.
4.
FornaroM, PrestiaD, ColicchioS, . A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287–304.
5.
Di GiannantonioM, Di IorioG, GuglielmoR, . Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011;25:109–114.
6.
TempestaD, MazzaM, IariaG, . A specific deficit in spatial memory acquisition in post-traumatic stress disorder and the role of sleep in its consolidation. Hippocampus. 2012;22:1154–163.
